Royalties Payments Sample Clauses
The 'Royalties & Payments' clause defines the financial obligations between parties regarding compensation for the use of intellectual property or other licensed materials. It typically outlines how royalties are calculated, the schedule and method of payments, and any reporting requirements, such as providing sales statements or audit rights. This clause ensures that the rights holder receives appropriate compensation and that both parties have a clear understanding of payment expectations, thereby reducing the risk of disputes over financial terms.
Royalties Payments. 3.1 LICENSEE shall make:
(a) royalty payments to LICENSOR for each royalty bearing copy of the Run-Time Software shipped hereunder by LICENSEE or distributed by any Third Party pursuant to Addendum B.
(b) payments for Technical Support to LICENSOR pursuant to Addendum B.
3.2 LICENSEE shall provide LICENSOR with calendar quarterly reports showing the quantity of Designated Equipment shipped or otherwise transferred to an End User by LICENSEE or Third Parties hereunder, as well as the gross revenue received by LICENSEE, commencing after the commercial release of the Designated
Royalties Payments. 2.1 Bioenvision shall pay to Stegram a royalty of 10% of net sale price for product sold directly by Bioenvision or any of its subsidiaries. Net sale price is defined as the total sale price charged by Bioenvision or its subsidiaries minus discounts and tax. After expiry of the last patent a royalty of 5% of net sales shall be payable so long as Bioenvision uses any Trademarks owned by Stegram.
2.2 If Bioenvision shall transfer rights acquired under the Agreement to a third party other than a subsidiary of Bioenvision any payments received, including mile-stone payments and royalties, shall be divided equally between the parties after deduction of development costs incurred by Bioenvision.
2.3 Bioenvision shall transfer to Stegram 100,000 shares in Bioenvision, Inc. within ninety (90) days of signing the definitive Agreement.
2.4 After three (3) years of the date of the definitive Agreement Bioenvision agrees to pay a minimum royalty of $50,000 per year. If sales of the Product(s) are not sufficient to meet the minimum royalty Bioenvision shall have the right to offset any excess payment against future royalties for up to two (2) years after the minimum royalty becomes payable.
2.5 Bioenvision shall purchase the existing stocks or Product and raw material and pharmaceutically prepared forms of the product from Stegram, provided they are in a good and stable condition and suitable to meet regulatory requirements for the sale or manufacture of pharmaceutical products. Thereafter Bioenvision shall be responsible for the manufacture of the raw material and pharmaceutical dose forms.
Royalties Payments. Lessee shall pay to Lessor, a four percent (4%) gross production royalty from the sale or disposition of minerals, metal and materials taken from “The Property” leased to Lessee and covered by this Lease. All payments made under this agreement shall be made to Lessor by Lessee within fifteen (15) days from that date that the buyer makes final settlement with Lessee. Payments shall be made either in person or to the address under which Lessor enters this agreement. Payment made to the Lessor shall be accompanied by the sales slip showing the basis upon which the sale has been made. All settlement sheets or sales slips shall be marked as sold from “The Property”. In consideration for this Lease, Lessee will pay Lessor $1000 upon signing, $5,000 March 15th 2004 and a minimum annual royalty of $6,000 Jan 1st 2005, $8,000 Jan 1st 2006, $10,000 Jan 1st 2007, $12,000 Jan 1st 2008 and $12,000 Jan 1st every year there after as long as this Lease is in effect. All minimum annual royalties shall be applied to actual royalties.
Royalties Payments. STOCK AND REIMBURSEMENT --------------------------------------------
Royalties Payments. 3.1. Royalties In consideration for the rights granted under Article II, LICENSEE shall make royalty payments to LICENSOR, pursuant to Addendum C, for the Run-Time Software shipped hereunder by LICENSEE or distributed by any Third Party.
Royalties Payments. 2.1 Bioenvision shall pay to WinWin a royalty of 10% of net sale price for Products sold directly by Bioenvision or any of its subsidiaries. Net sale price is defined as the total sale price charge by Bioenvision or its subsidiaries minus discounts and tax.
2.2 If Bioenvision shall transfer rights acquired under the Agreement to a third party other than a subsidiary of Bioenvision any payments received, including mile-stone payments and royalties, shall be divided equally between the parties after deduction of development costs incurred by Bioenvision, such costs will be limited to 20% of the payments received for such transfer.
Royalties Payments. 3.1. Royalties In consideration for the rights granted under Article II, except as provided in Article VI hereof, LICENSEE shall make royalty payments to LICENSOR for the Run-Time Software, pursuant to Addendum C.
3.2. Other Fees Any training provided by LICENSOR under this Agreement will be invoiced at the end of each month in which said services are provided at the then current fees. Unless otherwise provided in writing, all invoices are payable within thirty (30) days after invoice date.
Royalties Payments. No specific royalties shall be due under this Agreement for the grant of the License; however, the Parties hereby agree to supply the other Party’s reasonable requirements of Products for the pre-determined price. The Parties hereby agree that each Party shall maintain the exclusive right to manufacture its Product, and the Licensee shall purchase all EDCI Products exclusively from Licensor. Licensor shall purchase all BGF Products exclusively from Licensee. All other equipment required for construction and operation of a Project utilizing the Technology may be purchased from other vendors.
Royalties Payments. (a) In consideration of the rights hereby granted to Licensee in this Agreement, Licensee agrees to pay Licensor a license fee of fifty thousand dollars ($50,000.00) payable upon execution of this Agreement. A second license fee of seventy-five thousand dollars ($75,000.00) will be made to Licensor if Validation of the Manual Dipping Process is completed no later than 20 weeks after appropriate payment by Licensee to Licensor of funds (as set forth in (b) below) to develop the Validation and acquire the equipment necessary to assemble the Manual Dipping Process as more fully set forth in the definitions above. If Validation is not completed in this time period then the second license fee of seventy-five thousand dollars ($75,000.00) shall be reduced to fifty thousand dollars ($50,000.00) and shall be payable to Licensor upon completion of the Validation.
(b) Licensee shall pay to Licensor a one time fee of twenty thousand dollars ($20,000.00) prior to Licensor starting the Validation, and Licensee shall pay to Licensor a one time fee of one hundred thousand dollars ($100,000.00) prior to Licensor starting the design and installation of the Manual Dipping Process. The unit processing costs of $___ per unit of coated catheter for validation and qualification will be paid by Licensor.
(c) For each bi-annual period of Year 1 (as defined below) of this Agreement, Licensee shall pay to Licensor earned royalties in an amount that is the greater of $20,000 ("Year 1 Bi-Annual Minimum") or two percent (2%) of the Net Sales of Licensed Products sold by Licensee or its sublicensees ("Net Sales Royalty").
(d) For each bi-annual period of Year 2 of this Agreement, Licensee shall pay to Licensor earned royalties in an amount that is the greater of $30,000 ("Year 2 Bi-Annual Minimum") or two percent (2%) of the Net Sales of Licensed Products sold by Licensee or its sublicensees (Net Sales Royalty").
(e) For each bi-annual period of Year 3 and of succeeding years of this Agreement, Licensee shall pay to Licensor earned royalties in an amount that is the greater of $40,000 ("Year 3+ Bi-Annual Minimum") or two percent (2%) of the Net Sales of Licensed Products sold by Licensee or its sublicensees (Net Sales Royalty").
(f) The first bi-annual period (beginning of Year 1) of this Agreement shall commence on the earlier of January 1, 2002 or the first day of the calendar month in which the first commercial sale of Licensed Products by Licensee or its sub licensees occurs.
(g) R...
Royalties Payments. 4.1 In consideration of the license granted to ITAWASH under Article 2 for the Products, ITAWASH agrees to pay to CHINA MIX a royalty (hereinafter “the Royalty”) of (a) 1,25 Euros for any and each ITAWASH Made Product sold by ITAWASH as from the date of execution of this agreement as well as (b) 1,25 Euros for any and each Third Party Made Product purchased by ITAWASH from the Third Party Manufacturer as from the date of execution of this agreement.
4.2 Payment of the Royalty shall be made by ITAWASH to CHINA MIX as follows: (a) ITAWASH agrees to provide written reports comprising the product codes to CHINA MIX within thirty (30) days after the first of January, April, July and October of each calendar year stating in each such report the quantity of Products invoiced with respect to ITAWASH Made Products sold by ITAWASH and/or the quantity of Products invoiced with respect to Third Party Made Products purchased by ITAWASH from the Third Party Manufacturer during the preceding quarter and the total amount of Royalty payable therefore.